Biofrontera Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Biofrontera Inc. (BFRI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 815.09 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- Biofrontera Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares.
- Biofrontera Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 815.09K shares.
- Biofrontera Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was -34.35K shares, a 172.72% decline year-over-year.
- Biofrontera Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-12-31 was 47.23K shares, a 73.31% increase year-over-year.
- Biofrontera Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 719.84K shares, a 44.20% decline from fiscal 2024.
- Biofrontera Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.29M shares, a 2493.92% increase from fiscal 2023.
- Biofrontera Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 49.73K shares, a 22.99% decline from fiscal 2022.
- Biofrontera Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 64.57K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 815.09K shares 10-Q · filed 2026-08-13 | 780.74K shares derived: sum of 3 quarters · filed 2026-08-13 | ||
| 2026-03-31 | 815.09K shares 10-Q · filed 2026-05-14 | 780.74K shares derived: sum of 2 quarters · filed 2026-05-14 | |||
| 2025-12-31 | -34.35K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 719.84K shares 10-K · filed 2026-03-19 | |||
| 2025-09-30 | 754.19K shares 10-Q · filed 2025-11-12 | ||||
| 2024-12-31 | 47.23K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 1.29M shares 10-K · filed 2026-03-19 | |||
| 2024-09-30 | 1.24M shares 10-Q · filed 2024-11-14 | ||||
| 2023-12-31 | 27.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 27.25K shares derived: sum of 2 quarters · filed 2025-03-20 | -150.96K shares derived: sum of 3 quarters · filed 2025-03-20 | 49.73K shares 10-K · filed 2025-03-20 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -178.22K shares derived: sum of 2 quarters · filed 2023-11-09 | 22.48K shares 10-Q · filed 2023-11-09 | -1.29B shares derived: sum of 4 quarters · filed 2024-03-15 | |
| 2023-06-30 | -178.22K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | 22.48K shares 10-Q · filed 2023-08-11 | -1.29B shares derived: sum of 3 quarters · filed 2024-03-15 | -1.08B shares derived: sum of 4 quarters · filed 2024-03-15 | |
| 2023-03-31 | 200.69K shares 10-Q · filed 2023-05-12 | -1.29B shares derived: sum of 2 quarters · filed 2024-03-15 | -1.08B shares derived: sum of 3 quarters · filed 2024-03-15 | -28.11M shares derived: sum of 4 quarters · filed 2024-03-15 | |
| 2022-12-31 | -1.29B shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -1.08B shares derived: sum of 2 quarters · filed 2024-03-15 | -28.31M shares derived: sum of 3 quarters · filed 2024-03-15 | 64.57K shares 10-K · filed 2024-03-15 | 1.29M shares 10-K · filed 2023-03-13 |
| 2022-09-30 | 208.68M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 1.26B shares derived: sum of 2 quarters · filed 2022-11-14 | 1.29B shares 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | 1.05B shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 1.08B shares 10-Q · filed 2022-08-12 | |||
| 2022-03-31 | 28.38M shares 10-Q · filed 2022-05-13 | ||||
| 2021-12-31 | 30.94K shares 8-K · filed 2023-10-03 | 617.70K shares 10-K · filed 2022-04-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |